
ASX Announcement and Media Release

1 June 2005

SciGen Limited

Insulin sales to commence in Sri-Lanka

SciGen Limited ("SciGen") announced today that it had entered into a Commercialisation Agreement with the ABANS Group in Sri Lanka for the sale of SciLin™- SciGen's recombinant human insulin. Health registration is expected to take 12 months, after which the ABANS Group has committed to minimum purchases of US\$700,000 over the first 3 years.

The ABANS Group in Sri Lanka is a well established business involved in the sales of pharmaceuticals and medical devices. It has a current turnover of approximately US\$80 million and about 600 staff.

About SciGen

SciGen Ltd is a biopharmaceutical company involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland and the Netherlands.

=====ENDS=====

Media enquiries

Mark Compton

Managing Director & CEO: Telephone: +61 2 9234 1700: Web: www.scigen.com.au